This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Oct;19(10):1263-1264.

doi: 10.1016/S1470-2045(18)30530-8. Epub 2018 Sep 12.

Encorafenib plus binimetinib: an embarrassment of riches

Juan Martin-Liberal¹

Affiliations

Affiliation

¹ Melanoma, Sarcoma and Genitourinary Tumors Unit, Institut Català d'Oncologia (ICO) L'Hospitalet, 08907 Barcelona, Spain; Molecular Therapeutics Research Unit (UITM), Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain. Electronic address: jmartinliberal@gmail.com.

PMID: 30219625
DOI: 10.1016/S1470-2045(18)30530-8

Comment

Encorafenib plus binimetinib: an embarrassment of riches

Juan Martin-Liberal. Lancet Oncol. 2018 Oct.

. 2018 Oct;19(10):1263-1264.

doi: 10.1016/S1470-2045(18)30530-8. Epub 2018 Sep 12.

Author

Juan Martin-Liberal¹

Affiliation

¹ Melanoma, Sarcoma and Genitourinary Tumors Unit, Institut Català d'Oncologia (ICO) L'Hospitalet, 08907 Barcelona, Spain; Molecular Therapeutics Research Unit (UITM), Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain. Electronic address: jmartinliberal@gmail.com.

PMID: 30219625
DOI: 10.1016/S1470-2045(18)30530-8

No abstract available

PubMed Disclaimer

Comment on

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Dummer R, et al. Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Lancet Oncol. 2018. PMID: 30219628 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program